ULVERSTON'S GlaxoSmithKline (GSK) has shelved plans for a £350million biopharmaceutical facility.

GSK today set out several announcements made by the company to improve the 'efficiency and competitiveness of its manufacturing network'.

In a statement, the company said: "In pharmaceuticals, the company is to undertake a strategic review of its cephalosporins antibiotics business, with an option to sell the business including the associated manufacturing facilities.

MORE TOP STORIES:

"These medicines are produced at GSK sites in Ulverston, Cumbria, Verona in Italy and part of its Barnard Castle site. The Company has also decided to outsource some manufacturing activity at its Worthing site in the UK. GSK will continue to manufacture other antibiotics such as Augmentin and will continue to conduct research on new antibiotics.

"The company has also decided not to proceed with a previously planned investment to build a biopharmaceutical facility in Ulverston as it no longer needs the additional capacity."

The new facility was set to bring up to 350 new jobs to Ulverston.